Guangxi Liuyao Group (603368.SH) announced that the production capacity of the traditional Chinese medicine granule project is as follows: the total planned capacity of the project is 3,000 tons, of which the first-phase capacity is 1,500 tons. From January to August 2024, the company actively promoted the introduction of equipment, process optimization, and equipment technological transformation, accelerating the increase in production capacity. As of August 31, 2024, the production capacity of the traditional Chinese medicine granule project has reached 1,000 tons, which can better meet the company's market expansion needs. At the same time, the company further accelerated the follow-up of production capacity based on market development progress to ensure the company's supply advantages.
The company's situation of traditional Chinese medicine granule variety filing: From January to August 2024, the company continued to promote the filing of traditional Chinese medicine granule varieties, in addition to national and Guangxi provincial standard varieties, actively carried out provincial standard filing work in Guangdong, Sichuan, Chongqing, and other regions. As of August 31, 2024, the company completed the listing filing of 554 varieties in Guangxi, completed the cross-provincial sales filing of over 400 varieties in Guangdong, Guizhou, Sichuan, Chongqing, and completed the cross-provincial sales filing of over 200 varieties in Fujian, Anhui, Yunnan, and Hunan. The company has conducted variety filing in 16 provinces, laying the foundation for the company to expand the domestic and overseas markets.
The company's situation of traditional Chinese medicine granule market expansion: From January to August 2024, the company intensified the market expansion of traditional Chinese medicine granule products, established a professional marketing team for traditional Chinese medicine granules, and accelerated the development of downstream customers in the province by leveraging the company's wholesale sector and hospital channel advantages. Outside the province, the company promoted market development through agency, and as of August 31, 2024, the company has developed 832 customers (including 309 in the province and 523 outside the province, 48 at or above the tertiary hospitals, and 150 at or above the secondary hospitals), an increase of 426 from the end of 2023. The company will further accelerate the market layout in the next step to achieve increased sales volume.
